Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Testosterone enanthate Clear all
Completed Phase 3 Interventional Results available

Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

NCT02504541
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

NCT00695110
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 68 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Results available

Study of Testosterone and rHGH in FSHD

NCT03123913
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
Testosterone Enanthate, Somatropin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 2 Interventional

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

NCT00001079
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Testosterone enanthate, Megestrol acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration

NCT06393634
View directory record Official record
Conditions
Healthy
Interventions
Testosterone injection, Testosterone gel, Testosterone Oral
Drug
Lead sponsor
Sports Medicine Research and Testing Laboratory
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
South Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 9, 2026, 1:07 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD

NCT03674320
View directory record Official record
Conditions
COPD
Interventions
Testosterone Enanthate, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Role of 5-alpha Reductase in Mediating Testosterone Actions

NCT00493987
View directory record Official record
Conditions
Healthy
Interventions
Testosterone Enanthate, Dutasteride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2010 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

NCT01750398
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Testosterone cypionate, Goserelin, Leuprolide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 9, 2026, 1:07 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Effect of 5-Alpha Reductase on Testosterone in Men

NCT00070733
View directory record Official record
Conditions
Sex Disorders
Interventions
testosterone enanthate, duastride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years to 40 Years · Male only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2005 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Oral Testosterone for the Treatment of Hypogonadism

NCT01717768
View directory record Official record
Conditions
Hypogonadism
Interventions
TSX-002
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency

NCT00161304
View directory record Official record
Conditions
Men With Low Testosterone Levels
Interventions
Testosterone Enanthate, Placebo
Drug · Other
Lead sponsor
Leonard S. Marks, M.D.
Other
Eligibility
50 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Oral Testosterone for the Treatment of Hypogonadism in Males

NCT02222558
View directory record Official record
Conditions
Hypogonadism
Interventions
TSX-002
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 1 Interventional

Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults

NCT02203656
View directory record Official record
Conditions
Aging
Interventions
Placebo, Nutritional Supplement, In-home exercise, Testosterone
Drug · Dietary Supplement · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
65 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Results available

Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma

NCT00878995
View directory record Official record
Conditions
Cachexia, Squamous Cell Carcinoma
Interventions
Placebo Testosterone, Testosterone Enanthate 100 MG/ML
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 9, 2026, 1:07 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents

NCT02679274
View directory record Official record
Conditions
Aging
Interventions
Placebo, Testosterone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Galveston, Texas • Texas City, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Sep 9, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Testosterone Administration and ACL Reconstruction in Men

NCT01595581
View directory record Official record
Conditions
Muscle Atrophy, ACL Reconstruction, Trauma, Osteoarthritis
Interventions
Testosterone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 9, 2026, 1:07 PM EDT
Recruiting Phase 2 Interventional

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT04363164
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionate, Enzalutamide, Testosterone enanthate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 9, 2026, 1:07 PM EDT